Philips, Celsion ink ultrasound research deal for cancer treatment
Royal Philips Electronics and Celsion have signed a research agreement to combine Philips’ ultrasound technology with Celsion’s drug delivery solution to target tumors with high concentrations of a cancer-fighting drug.
Under the terms of the agreement, Philips and the Columbia, Md.-based Celsion will collaborate to explore using Philips’ MRI-guided high intensity focused ultrasound (HIFU) system in combination with Celsion’s drug candidate, ThermoDox.
The research uses the HIFU system to position doxorubicin, an approved cancer drug to create a mild hyperthermia that releases the drug directly into the tumor. The result would be the ability to treat tumors that would otherwise be inaccessible, the companies said.
The Philips’ HIFU, designed to control and deliver energy non-invasively to targeted tissues, is being researched to evaluate its use in activating Celsion’s temperature-sensitive liposome technology to release encapsulated chemotherapy drugs such as doxorubicin. Doxorubicin is the anticancer agent in ThermoDox.
Under the terms of the agreement, Philips and the Columbia, Md.-based Celsion will collaborate to explore using Philips’ MRI-guided high intensity focused ultrasound (HIFU) system in combination with Celsion’s drug candidate, ThermoDox.
The research uses the HIFU system to position doxorubicin, an approved cancer drug to create a mild hyperthermia that releases the drug directly into the tumor. The result would be the ability to treat tumors that would otherwise be inaccessible, the companies said.
The Philips’ HIFU, designed to control and deliver energy non-invasively to targeted tissues, is being researched to evaluate its use in activating Celsion’s temperature-sensitive liposome technology to release encapsulated chemotherapy drugs such as doxorubicin. Doxorubicin is the anticancer agent in ThermoDox.